[1]
|
Holtan, S.G., Pasquini, M. and Weisdorf, D.J. (2014) Acute Graft-versus-Host Disease: A Bench-to-Bedside Update. Blood, 124, 363-373. https://doi.org/10.1182/blood-2014-01-514786
|
[2]
|
Chen, Y., Zhao, Y., Cheng, Q., et al. (2015) The Role of Intestinal Microbiota in Acute Graft-versus-Host Disease. Journal of Immunology Research, 2015, Article ID: 145859. https://doi.org/10.1155/2015/145859
|
[3]
|
Penack, O., Marchetti, M., Ruutu, T., et al. (2020) Prophylaxis and Management of Graft versus Host Disease after Stem-Cell Transplantation for Haematological Malig-nancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation. The Lancet Haematology, 7, e157-e167.
https://doi.org/10.1016/S2352-3026(19)30256-X
|
[4]
|
Yu, J., Judy, J.T., Parasuraman, S., et al. (2020) Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, Following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 26, 600-605.
https://doi.org/10.1016/j.bbmt.2019.10.028
|
[5]
|
German National Bone Marrow Donor Registry (2020) German Standards for Unrelated Blood Stem Cell Donations.
|
[6]
|
Holler, E., Greinix, H. and Zeiser, R. (2019) Acute Graft-versus-Host Disease. In: Carreras, E., Dufour, C., Mohty, M. and Kröger, N., Eds., The EBMT Handbook: Hem-atopoietic Stem Cell Transplantation and Cellular Therapies, Springer, Berlin, 323-330. https://doi.org/10.1007/978-3-030-02278-5_43
|
[7]
|
Bai, Y., Lei, J.-H. and Guan, F. (2021) Research Progress on the Role and Mechanisms of IL-33 ST2 Signaling Pathway in Liver Disease#br#. Journal of Tropical Diseases and Parasitology, 19, 41-46.
|
[8]
|
Dwyer, G.K., Mathews, L.R., Villegas, J.A., et al. (2022) IL-33 Acts as a Costimulatory Signal to Generate Alloreactive Th1 Cells in Graft-versus-Host Disease. The Journal of Clinical Investigation, 132, e150927.
https://doi.org/10.1172/JCI150927
|
[9]
|
Ferrara, J. and Prado-Acosta, M. (2022) Graft-versus-Host Disease: Es-tablishing IL-33 as an Important Costimulatory Molecule. The Journal of Clinical Investigation, 132, e150927. https://doi.org/10.1172/JCI160692
|
[10]
|
Liu, O., Xu, J., Wang, F., et al. (2021) Adipose-Mesenchymal Stromal Cells Suppress Experimental Sjögren Syndrome by IL-33-Driven Expansion of ST2+ Regulatory T Cells. Iscience, 24, Article ID: 102446.
https://doi.org/10.1016/j.isci.2021.102446
|
[11]
|
Onda, H., Kasuya, H., Takakuza, K., et al. (1999) Identification of Genes Differentially Expressed in Canine Vesespastic Cerebral Arteries after Subarachnoid Hemorrhage. Journal of Cerebral Blood Flow & Metabolism, 19, 1279-1288. https://doi.org/10.1097/00004647-199911000-00013
|
[12]
|
Baekkevold, E.S., Roussigné, M., Yamanaka, T., et al. (2003) Molecular Characterization of NF-HEV, a Nuclear Factor Preferentially Expressed in Human High Endothelial Venules. The American Journal of Pathology, 163, 69-79.
https://doi.org/10.1016/S0002-9440(10)63631-0
|
[13]
|
Sehmitz, J., Owyang, A., Oldham, E., et al. (2005) IL-33, an Interleukin-1-Like Cytokine That Signals via the IL-1 Receptorrelated Protein ST2 and Induces T Helper Type 2-Associated Cytokines. Immunity, 23, 479-490.
https://doi.org/10.1016/j.immuni.2005.09.015
|
[14]
|
钟农萍, 张剑. 白细胞介素-33/ST2信号转导系统与变应性鼻炎[J]. 国际耳鼻咽喉头颈外科杂志, 2015, 39(2): 77-80.
|
[15]
|
Cayrol, C. and Girard, J.P. (2018) Interleukin‐33 (IL‐33): A Nuclear Cytokine from the IL‐1 Family. Immunological Reviews, 281, 154-168. https://doi.org/10.1111/imr.12619
|
[16]
|
Liew, F.Y., Girard, J.P. and Turnquist, H.R. (2016) Interleukin-33 in Health and Disease. Nature Reviews Immunology, 16, 676-689. https://doi.org/10.1038/nri.2016.95
|
[17]
|
Drake, L.Y. and Kita, H. (2017) IL‐33: Biological Properties, Functions, and Roles in Airway Disease. Immunological Reviews, 278, 173-184. https://doi.org/10.1111/imr.12552
|
[18]
|
Guo, H., Bossila, E.A., Ma, X., et al. (2022) Dual Immune Regulatory Roles of Interleukin-33 in Pathological Conditions. Cells-Basel, 11, Article No. 3237. https://doi.org/10.3390/cells11203237
|
[19]
|
Saba, J.B. and Turnquist, H.R. (2023) The Reparative Roles of IL-33. Transplantation, 107, 1069-1078.
https://doi.org/10.1097/TP.0000000000004447
|
[20]
|
Liu, Q., Dwyer, G.K., Zhao, Y., et al. (2019) IL-33-Mediated IL-13 Secretion by ST2+ Tregs Controls Inflammation after Lung Injury. JCI Insight, 4, e123919. https://doi.org/10.1172/jci.insight.123919
|
[21]
|
Seltmann, J., Werfel, T. and Wittmann, M. (2013) Evidence for a Regulatory Loop between IFN‐γ and IL‐33 in Skin Inflammation. Experimental Dermatology, 22, 102-107. https://doi.org/10.1111/exd.12076
|
[22]
|
Dahlgren, M.W., Jones, S.W., Cautivo, K.M., et al. (2019) Adventitial Stromal Cells Define Group 2 Innate Lymphoid Cell Tissue Niches. Immunity, 50, 707-722.E6. https://doi.org/10.1016/j.immuni.2019.02.002
|
[23]
|
Sundlisæter, E., Edelmann, R.J., Hol, J., et al. (2012) The Alarmin IL-33 Is a Notch Target in Quiescent Endothelial Cells. The American Journal of Pathology, 181, 1099-1111. https://doi.org/10.1016/j.ajpath.2012.06.003
|
[24]
|
Kurowska-Stolarska, M., Stolarski, B., Kewin, P., et al. (2009) IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway Inflammation. The Journal of Immunology, 183, 6469-6477.
https://doi.org/10.4049/jimmunol.0901575
|
[25]
|
Yanagisawa, K., Takagi, T., Tsukamoto, T., et al. (1993) Presence of a Novel Primary Response Gene ST2L, Encoding a Product Highly Similar to the Interleukin 1 Receptor Type 1. FEBS Letters, 318, 83-87.
https://doi.org/10.1016/0014-5793(93)81333-U
|
[26]
|
Thanikachalama, P.V., Ramamurthy, S., Mallapu, P., et al. (2023) Modulation of IL-33/ST2 Signaling as a Potential New Therapeutic Target for Cardiovascular Diseases. Cytokine & Growth Factor Reviews, 71-72, 94-104.
https://doi.org/10.1016/j.cytogfr.2023.06.003
|
[27]
|
Lipsky, B.P., Toy, D.Y., Swart, D.A., et al. (2012) Deletion of the ST2 Proximal Promoter Disrupts Fibroblast‐Specific Expression but Does Not Reduce the Amount of Soluble ST2 in Circulation. European Journal of Immunology, 42, 1863-1869. https://doi.org/10.1002/eji.201142274
|
[28]
|
Aimo, A., Januzzi, J.L., Bayes-Genis, A., et al. (2019) Clinical and Prognostic Significance of SST2 in Heart Failure: JACC Review Topic of the Week. Journal of the American College of Cardiology, 74, 2193-2203.
https://doi.org/10.1016/j.jacc.2019.08.1039
|
[29]
|
Griesenauer, B. and Paczesny, S. (2017) The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Frontiers in Immunology, 8, Article No. 475. https://doi.org/10.3389/fimmu.2017.00475
|
[30]
|
Homsak, E. and Gruson, D. (2020) Soluble ST2: A Complex and Diverse Role in Several Diseases. Clinica Chimica Acta, 507, 75-87. https://doi.org/10.1016/j.cca.2020.04.011
|
[31]
|
Dinarello, C.A. (2011) Interleukin-1 in the Pathogenesis and Treat-ment of Inflammatory Diseases. Blood, the Journal of the American Society of Hematology, 117, 3720-3732. https://doi.org/10.1182/blood-2010-07-273417
|
[32]
|
刘天聪, 王大南, 吕昌龙. IL-33及其受体ST2在炎症性肠病中免疫调节作用的研究新进展[J]. 国际免疫学杂志, 2012, 35(4): 269-272.
|
[33]
|
Sun, Y., Wen, Y., Wang, L., et al. (2021) Therapeutic Opportunities of Interleukin-33 in the Central Nervous System. Frontiers in Immunology, 12, Article ID: 654626. https://doi.org/10.3389/fimmu.2021.654626
|
[34]
|
吴秀华, 郑文洁. 白细胞介素-33/ST2通路研究进展及其在系统性血管炎发病机制中作用[J]. 中华内科杂志, 2015(4): 368-370.
|
[35]
|
霍永宝, 于水莲, 陶怡. 白细胞介素-33/ST2通路在风湿免疫性疾病中作用的研究进展[J]. 中华风湿病学杂志, 2015, 19(9): 627-630.
|
[36]
|
Baumann, C., Fröhlich, A., Brunner, T.M., et al. (2019) Memory CD8+ T Cell Protection from Viral Re-infection Depends on Interleukin-33 Alarmin Signals. Frontiers in Immunology, 10, Article No. 1833.
https://doi.org/10.3389/fimmu.2019.01833
|
[37]
|
Justiz Vaillant, A.A., Modi, P. and Mohammadi, O. (2022) Graft versus Host Disease. StatPearls Publishing, Treasure Island.
|
[38]
|
Matsuoka, S., Hashimoto, D., Kadowaki, M., et al. (2020) Myeloid Differentiation Factor 88 Signaling in Donor T Cells Accelerates Graft-versus-Host Disease. Haemato-logica, 105, 226-234.
https://doi.org/10.3324/haematol.2018.203380
|
[39]
|
Mantovani, A., Dinarello, C.A., Molgora, M., et al. (2019) In-terleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity, 50, 778-795. https://doi.org/10.1016/j.immuni.2019.03.012
|
[40]
|
Matta, B.M., Reichenbach, D.K., Zhang, X., et al. (2016) Pe-ri-AlloHCT IL-33 Administration Expands Recipient T-Regulatory Cells That Protect Mice against Acute GVHD. Blood, the Journal of the American Society of Hematology, 128, 427-439. https://doi.org/10.1182/blood-2015-12-684142
|
[41]
|
Vander Lugt, M.T., Braun, T.M., Hanash, S., et al. (2013) ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death. The New England Journal of Medicine, 369, 529-539.
https://doi.org/10.1056/NEJMoa1213299
|
[42]
|
Cantilena, C.R., Ito, S., Tian, X., et al. (2018) Distinct Biomarker Profiles in ex Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection versus CD3+/19+ Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 24, 460-466.
https://doi.org/10.1016/j.bbmt.2017.11.028
|
[43]
|
Griesenauer, B., Jiang, H., Yang, J., et al. (2020) ST2/MyD88 Deficiency Protects Mice against AGVHD and Spares T-Regulatory Cells. The Journal of Immunology, 202, 3053-3064. https://doi.org/10.4049/jimmunol.1800447
|
[44]
|
Hill, G.R., Betts, B.C., Tkachev, V., et al. (2021) Current Concepts and Advances in Graft-versus-Host Disease Immunology. Annual Review of Immunology, 39, 19-49. https://doi.org/10.1146/annurev-immunol-102119-073227
|
[45]
|
Griesenauer, B. and Paczesny, S. (2017) The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Frontiers in Immunology, 8, Article No. 475. https://doi.org/10.3389/fimmu.2017.00475
|
[46]
|
Reichenbach, D.K., Schwarze, V., Matta, B.M., et al. (2015) The IL-33/ST2 Axis Augments Effector T-Cell Responses during Acute GVHD. Blood, the Journal of the American Society of Hematology, 125, 3183-3192.
https://doi.org/10.1182/blood-2014-10-606830
|
[47]
|
Rao, U.K. and Engelhardt, B.G. (2020) Predicting Immu-no-Metabolic Complications after Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and Its Receptor Serum-Stimulation 2 (ST2). Clinical Hematology International, 2, 101-108. https://doi.org/10.2991/chi.d.200506.002
|
[48]
|
Zhang, J., Ramadan, A.M., Griesenauer, B., et al. (2015) ST2 Blockade Reduces SST2-Producing T Cells While Maintaining Protective MST2-Expressing T Cells during Graft-versus-Host Disease. Science Translational Medicine, 7, 308ra160. https://doi.org/10.1126/scitranslmed.aab0166
|
[49]
|
Matsumura-Kimoto, Y., Inamoto, Y., Tajima, K., et al. (2016) Association of Cumulative Steroid Dose with Risk of Infection after Treatment for Severe Acute Graft-versus-Host Dis-ease. Biology of Blood and Marrow Transplantation, 22, 1102-1107. https://doi.org/10.1016/j.bbmt.2016.02.020
|
[50]
|
Rashidi, A., De For, T.E., Holtan, S.G., Blazar, B.R., Weisdorf, D.J. and MacMillan, M.L. (2019) Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 2297-2302. https://doi.org/10.1016/j.bbmt.2019.07.017
|
[51]
|
Maria, A.T., Maumus, M., Le Quellec, A., Jorgensen, C., Noel, D. and Guilpain, P. (2017) Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Per-spectives for Systemic Sclerosis. Clinical Reviews in Allergy & Immunology, 52, 234-259. https://doi.org/10.1007/s12016-016-8552-9
|
[52]
|
Caplan, A.I. (1991) Mesenchymal Stem Cells. Journal of Ortho-paedic Research, 9, 641-650.
https://doi.org/10.1002/jor.1100090504
|
[53]
|
Spaggiari, G.M., Abdelrazik, H., Becchetti, F. and Moretta, L. (2009) MSCs Inhibit Monocyte-Derived DC Maturation and Function by Selectively Interfering with the Generation of Imma-ture DCs: Central Role of MSC-Derived Prostaglandin E2. Blood, 113, 6576-6583. https://doi.org/10.1182/blood-2009-02-203943
|
[54]
|
Zuk, P.A., Zhu, M., Mizuno, H., et al. (2001) Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies. Tissue Engineering, 7, 211-228. https://doi.org/10.1089/107632701300062859
|
[55]
|
Lee, D.E., Ayoub, N. and Agrawal, D.K. (2016) Mesenchymal Stem Cells and Cutaneous Wound Healing: Novel Methods to Increase Cell Delivery and Therapeutic Efficacy. Stem Cell Research & Therapy, 7, Article No. 37.
https://doi.org/10.1186/s13287-016-0303-6
|
[56]
|
Mashiko, T., Takada, H., Wu, S.H., et al. (2018) Therapeutic Ef-fects of a Recombinant Human Collagen Peptide Bioscaffold with Human Adipose‐Derived Stem Cells on Impaired Wound Healing after Radiotherapy. Journal of Tissue Engineering and Regenerative Medicine, 12, 1186-1194. https://doi.org/10.1002/term.2647
|
[57]
|
韩月霞. 脂肪源间充质干细胞体外对AGVHD患者T细胞亚群的影响及机制初探[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2021.
|
[58]
|
Blanco, B., Herrero-Sánchez, M.C., Rodríguez-Serrano, C., et al. (2016) Immunomodulatory Effects of Bone Marrow versus Adipose Tissue‐Derived Mes-enchymal Stromal Cells on NK Cells: Implications in the Transplantation Setting. European Journal of Haematology, 97, 528-537. https://doi.org/10.1111/ejh.12765
|
[59]
|
Chen, Y., Zuo, J., Chen, W., et al. (2019) The Enhanced Effect and Underlying Mechanisms of Mesenchymal Stem Cells with IL-33 Overexpression on Myocardial Infarction. Stem Cell Research & Therapy, 10, Article No. 1.
https://doi.org/10.1186/s13287-018-1105-9
|
[60]
|
Martínez-González, I., Roca, O., Masclans, J.R., et al. (2013) Human Mesenchymal Stem Cells Overexpressing the IL-33 Antagonist Soluble IL-1 Receptor-Like-1 Attenuate Endo-toxin-Induced Acute Lung Injury. American Journal of Respiratory Cell and Molecular Biology, 49, 552-562. https://doi.org/10.1165/rcmb.2012-0406OC
|